Low Dose Naltrexone & Cancer

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.


Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.


Low Dose Naltrexone in Dermatology.


Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.


Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.


The Use of Naltrexone in Low Doses Beyond the Approved Indication.


Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.


Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.


Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.


The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.


Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.


Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats.


Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.


The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous alpha-Lipoic Acid/Low-Dose Naltrexone Protocol.


Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.


Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.


Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment.


Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.


Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.


Low-dose naltrexone: harnessing the body's own chemistry to treat human ovarian cancer.


Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need.


Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).


Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.


Low-dose naltrexone for disease prevention and quality of life.


The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.


Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report.


In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop for psoriasis.


A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.


Oxycodone combined with opioid receptor antagonists: efficacy and safety.


The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.


Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone.


Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.


Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.


Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials.


The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma.


Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.


Inhibitory effect of low-dose pentazocine on the development of antinociceptive tolerance to morphine.

Advances in induction of ovulation.


Selective opioid growth factor receptor antagonists based on a stilbene isostere.


Acquired immunodeficiency syndrome: molecular biology and its therapeutic intervention (review).


Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.


Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.


Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.


Metabolic treatment of cancer: intermediate results of a prospective case series.


Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study.


High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.


Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.


Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.


Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.


Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report.


Epidemiologic and molecular pathophysiology of chronic opioid dependence and the place of naltrexone extended-release formulations in its clinical management.


Independent expression of two pharmacologically distinct supraspinal mu analgesic systems in genetically different mouse strains.